Company: OCEA
Filing Date: 2025-01-13
Form Type: 10-Q
Source: 0001493152-25-001880
Chunk: 63

Company: Ocean Biomedical, Inc.
Filing Date: 2025-01-13
Form: 10-Q
Item: Item 1
Chunk 63
---
 the conversion of such instruments
would be dilutive. The Company’s potentially dilutive securities, which include stock options, earnout shares, and warrants to
purchase shares of common stock, have been excluded from the computation of diluted net loss per share as the effect would be to reduce
the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted
net loss per share attributable to the Company’s stockholders’ is the same.

The
net loss per share for the basic and diluted earnings calculations for the three and nine months ended September 30, 2024 and 2023 is
as follows (in thousands, except share and per share data):

 Schedule of Earnings Per Share, Basic and Diluted

    2024  
    2023  
    2024  
    2023 

    Three Months Ended  September 30,  
    Nine months Ended  September 30, 

    2024  
    2023  
    2024  
    2023 
  
    Numerator: 

    Net loss 
    $(5,528) 
    $(14,087) 
    $(9,763) 
    $(97,610)
  
    Denominator: 

    Weighted-average shares of common stock outstanding, basic and diluted 
     27,487,283  
     26,605,147  
     27,446,868  
     25,980,292 
  
    Net loss per common share, basic and diluted 
    $(0.20) 
    $(0.53) 
    $(0.36) 
    $(3.76)

As
noted above, the following securities were excluded from the computation of diluted loss per share in the periods presented, as their
effect would be anti-dilutive:

 Schedule of Securities Excluded From Computation of Diluted Loss Per Share 

    2024  
    2023  
    2024  
    2023 

    Three Months Ended September 30,  
    Nine months Ended September 30, 

    2024  
    2023  
    2024  
    2023 
  
    Stock options 
     600,000  
     600,000  
     600,000  
     600,000